A Pilot Study of Dose-Dense Paclitaxel with Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer
Antineoplastic Combined Chemotherapy Protocols
Neoplasm Recurrence, Local
The discontinuation rate during DD PTL was high, owing, in part, to an unexpectedly high incidence of rash. The trial was halted, because the initial discontinuation rate from overall toxicity made it unlikely that full accrual would demonstrate feasibility.